Drug Trial Radar · NCT06095102
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
311
Actual
Start
Oct 12, 2023
Primary completion
Jun 19, 2024
Study completion Feb 17, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Conditions
- Plaque Psoriasis
Interventions
JNJ-77242113Drug
JNJ-77242113 will be administered orally.
PlaceboDrug
Placebo will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16Time frame: Week 16
Locations
90 sites in 11 countries. Site status is shown where the registry gives one.
Center for Dermatology and Plastic Surgery
Scottsdale, Arizona
Johnson Dermatology
Fort Smith, Arkansas
California Dermatology & Clinical Research Institute
Encinitas, California
Forcare Clinical Research Inc
Tampa, Florida
Hamilton Research LLC
Alpharetta, Georgia
Arlington Dermatology
Rolling Meadows, Illinois
Dundee Dermatology
West Dundee, Illinois
Dawes Fretzin Clinical Research Group LLC
Indianapolis, Indiana
Indiana Clinical Trial Center
Plainfield, Indiana
Dermatology and Advanced Aesthetics
Lake Charles, Louisiana
Allcutis Research 1
Beverly, Massachusetts
Hamzavi Dermatology
Fort Gratiot, Michigan
Minnesota Clinical Study Center
New Brighton, Minnesota
MediSearch Clinical Trials
Saint Joseph, Missouri
Skin Specialists
Omaha, Nebraska
Schweiger Dermatology Group
East Windsor, New Jersey
Optima Research
Boardman, Ohio
Oregon Dermatology and Research Center
Portland, Oregon
Paddington Testing Co, Inc.
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Arlington Research Center, Inc.
Arlington, Texas
Center for Clinical Studies 1
Houston, Texas
Austin Institute for Clinical Research
Pflugerville, Texas
Progressive Clinical Research
San Antonio, Texas
Dermatology Clinical Research Center of San Antonio
San Antonio, Texas
Center for Clinical Studies
Webster, Texas
Cope Family Medicine - Ogden Clinic
Bountiful, Utah
Frontier Derm Partners CRO, LLC
Mill Creek, Washington
CIPREC
Buenos Aires, Argentina
Centro Privado de Medicina Familiar
Buenos Aires, Argentina
CEDIC Centro de Investigacion clinica
Caba, Argentina
Conexa Investigacion Clinica S.A.
CABA, Argentina
Alberta DermaSurgery Centre
Edmonton, Alberta, Canada
Lynderm Research Inc.
Markham, Ontario, Canada
Skin Centre for Dermatology
Peterborough, Ontario, Canada
York Dermatology Clinic and Research Centre
Richmond Hill, Ontario, Canada
Innovaderm Research Inc.
Montreal, Quebec, Canada
Centre De Recherche Dermatologique Du Quebec Metropolitain
Québec, Quebec, Canada
Skinsense Medical Research
Saskatoon, Saskatchewan, Canada
ISA - Interdisciplinary Study Association GmbH
Berlin, Germany
Showing 40 of 90 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.